Abstract
CD4+ regulatory T cells (TREG) are important contributors to the induction and maintenance of peripheral tolerance. It is now becoming evident that this heterogeneous population consists of naturally occurring and induced CD4+ TREG cells that share between themselves key immunoregulatory characteristics. Their phenotype and function often relies on the expression of Foxp3 transcription factor (TF) and the presence of the immunomodulating cytokine TGF-β 1. The interdependence of TGF-β 1 and Foxp3 in the induction and maintenance of regulatory T cell networks is gradually being elucidated, shedding new light on peripheral tolerance. Thus, comprehension and delimitation of those processes predict the development of novel therapies for the treatment of infectious and autoimmune diseases, cancer and graft rejection.
Keywords: CD4+CD25+ regulatory T cells, Foxp3, TGF-β1, IL-10, tolerance
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Safety
Current Drug Targets
Current Medicinal Chemistry
Current Pharmaceutical Biotechnology
Central Nervous System Agents in Medicinal Chemistry
Letters in Drug Design & Discovery
Current Drug Discovery Technologies
Recent Advances in Anti-Infective Drug Discovery
Related Books
test ebook
Computer-Aided Drug Discovery Methods: A Brief Introduction
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Frontiers in Drug Design and Discovery
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part II
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part I
Frontiers in Cardiovascular Drug Discovery
Frontiers in Drug Design and Discovery
Frontiers in Anti-Cancer Drug Discovery
Frontiers in Drug Design and Discovery
2